What is Asicor used for?

Adults Short-term therapy (up to 48 hours) of severe cardiac failure, which is not satisfactorily treatable with the usual treatment regimen (cardiac glycosides, diuretics, vasodilators, and angiotensin converting enzyme (ACE) inhibitors). During treatment with milrinone infusion, continuous monitoring of ECG, blood pressure must be ensured. Children In children, milrinone is indicated for short-term therapy (up to 35 hours) of congestive heart failure that is not responsive to

What pharmaceutical form is Asicor available in?

Asicor: Koncentrat do sporządzania roztworu do infuzji 1 mg/ml (dożylna)

Is Asicor OTC or prescription only?

Asicor requires a doctor's prescription.

What are the side effects of Asicor?

The frequencies for side effects are based on the following categories: Very common (≥1/10) Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100) Rare (≥1/10,000 to <1/1,000) Very rare (<1/10,000) Not known (cannot be estimated from the available data) SYSTEM ORGAN CLASS Common Uncommon Rare Very rare Not known Disorders of the blood and of the lymphatic system Thrombocytopenia 1 Reduction of RBC count and Hb concentration Disorders of immune system Anaphylactic shock Metabolism And nutrition d

Who should NOT take Asicor?

- Hypersensitivity to milrinone or any of the excipients listed in section 6.1, - Severe obstructive aortic or pulmonary valve disease, - Hypertrophic obstructive cardiomyopathy, - Ventricular aneurysm, - Severe, previously untreated hypovolemia, - Acute myocardial infarction. Milrinone must not be used in patients with cardiac failure due to hyperthyroidism, acute myocarditis or Amyloid cardiomyopathy, as there is insufficient therapy experience.

Does Asicor interact with other medications?

Fluid and electrolyte changes should be monitored as carefully as the serum creatinine level during Milrinone therapy. Milrinone and diuretics can mutually reinforce their effects. Cumulative diuretic and hypokalemic effects were observed. Milrinone enhances renal perfusion by increasing cardiac output, increasing the effect of diuretics and may thus require a reduction in diuretic dosing. Potassium loss due to excessive diuresis favor the onset of arrhythmias in digitalized pa

Can Asicor be used during pregnancy?

Pregnancy Currently there is little or no experience with the use of milrinone in pregnant women. Animal studies have not indicated any direct or indirect harmful effects to reproductive toxicity (see section 5.3). As a precautionary measure, use of milrinone during pregnancy should be avoided. Breast feeding It is unknown if milrinone or its metabolites are excreted in breast milk. A risk for the newborn / child cannot be excluded. A decision must be made whether to discontinu

What precautions should be taken with Asicor?

Instructions for dilution and administration: Infusion solutions should be freshly prepared before use. The following diluents may be used to prepare solutions for infusion: • 0.9% Sodium Chloride Infusion • 5% Glucose Infusion Initial dose The initial dose is 50 micrograms (0.05 mg) of milrinone/kg. It is administered slowly over a period of 10 minutes. This is usually followed by a continuous maintenance infusion. Maintenance dose The maintenance dose is generally 0.5 microgr

Who manufactures Asicor?

Pharmaselect International Beteiligungs GmbH (Austria)

What ATC class does Asicor belong to?

Asicor: ATC C01CE02. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

Asicor

This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.

Pharmacotherapeutic group: phosphodiesterase inhibitors. ATC code: C01CE02. Milrinone is a positive inotropic and vasodilating substance with low chronotropic, bathmotropic and dromotropic effects. It differs in structure and mode of action from both the digitalis glycosides and the catecholamines. Milrinone is a selective inhibitor of the peak-III- cAMP -phosphodiesterase -isoenzyme in myocardium and the tunica media at inotropic and vasorelaxant concentrations.‍‍‍‍‍‍‍ This inhibitory effect leads to a cAMP-mediated increase in intracellular Ca 2+ in the myocardial cell and the contraction force of the myocardium as well as cAMP dependent phosphorylation of the contractile proteins. In the tunica media cells, there is a cAMP mediated decrease of the intracellular Ca 2+ and thus leads to a relaxation of the vascular musculature. Further experimental evidence suggests that milrinone is neither a beta-receptor agonist nor does it resemble the Na + /Ka + ATPase inhibitory effect of digitalis glycosides. Clinical trials in cardiac failure patients have shown that milrinone increases the rate of maximum left ventricular pressure rise as a function of the dose and its plasma concentration. Studies in healthy volunteers have shown an increase in left ventricular pressure-volume relationship during milrinone therapy. This indicates a direct inotropic effect of the substance. Milrinone also resulted in a dose and plasma concentration dependent increase in forearm blood flow in patients with cardiac failure, indicating a direct vasodilatory effect on the arteries. In addition to increasing myocardial contractility, milrinone improves diastolic function. This was demonstrated by improvements in left ventricular diastolic relaxation. In patients with impaired myocardial function, milrinone injection in the usual dose range increased cardiac index and decreased pulmonary capillary pressure and vascular resistance. The heart rate increased by 3% to 10% depending on the dose. The mean arterial blood pressure fell dose dependently by 5% to 17%. The hemodynamic improvements correlated with dose and milrinone plasma concentration and were accompanied by improvement in clinical symptoms. The vast majority of patients showed improvements in hemodynamic parameters within five to fifteen minutes of treatment initiation. Milrinone also has a positive inotropic effect in digitalized patients. There is no evidence that milrinone increases the toxicity of glycosides. Approximately maximum effects of milrinone on cardiac output and pulmonary capillary pressure are attained at milrinone plasma concentrations ranging from 150 ng/ml to 250 ng/ml. Children and adolescents: Upon reviewing the literature, there were clinical studies in patients treated for low-cardiac output syndrome status post cardiac surgery due to septic shock or pulmonary hypertension. The usual dosage consisted of an initial dose from 50 to 75 microgram/kg for 30 to 60 minutes followed by a continuous intravenous infusion of 0.25 to 0.75 microgram/kg / min for up to 35 hours. In these studies, milrinone showed an increase in cardiac output, a decrease in cardiac filling pressure, and a decrease in systemic and pulmonary vascular resistance, along with a minimal change in heart rate and myocardial oxygen consumption. There are inadequate studies on prolonged use of milrinone to recommend a duration of more than 35 hours. Some studies have investigated the use of milrinone in children with non-hyperdynamic septic shock, the effect of milrinone on postsurgical pulmonary hypertension after bypass to correct a Tetralogy of Fallot and the combined effect of nitric oxide and milrinone on pulmonary circulation after Fontan surgery. The study results were not conclusive. Therefore, milrinone cannot be recommended for these indications.

Asicor

User Reviews